Open AccessSuccessful treatment with nivolumab in a patient with lung adenocarcinoma complicated by pulmonary aspergilloma
Author(s) -
Furuya Naoki,
Kojima Koji,
Marushima Hideki,
Kakinuma Kazutaka,
Tsunoda Akihito,
Koda Eriko,
Tsuruoka Hajime,
Nishida Kohei,
Inoue Takeo,
Saji Hisashi,
Mineshita Masamichi
Publication year - 2020
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.13662
Subject(s) - medicine , nivolumab , aspergilloma , lung cancer , adenocarcinoma , lung , oncology , aspergillosis , pneumonectomy , immune system , immunotherapy , surgery , cancer , immunology
Immune checkpoint inhibitors (ICIs) are the key drugs used in patients with non‐small cell lung cancer (NSCLC). However, anti‐PD‐1 therapy might worsen chronic infection by reactivating the immune response to infectious diseases. Here, we describe a case of successful treatment with nivolumab in a patient with NSCLC complicated by pulmonary aspergilloma, which was safely treated by surgical resection before administration of nivolumab. In conclusion, to safely treat patients with locally limited chronic pulmonary aspergillosis (CPA), surgical resection should be considered before ICI therapy.